Composition
Medicinal product in 100 ml. contains as active ingredients:
calcium gluconate monohydrate – 3.10 g;
calcium borgluconate – 42.90 g;
calcium hydroxide – 1.32 g;
magnesium chloride hexahydrate – 6.5 g;
2-aminoethyl dihydrogen phosphate – 0.60 g.
Pharmacological properties
Calcite C50 belongs to the group of products containing calcium, phosphorus, magnesium. The effect of the drug is determined by the effect of the constituent components.
Calcium is involved in the formation of bone tissue (prevents the risk of rickets and osteodystrophy), blood coagulation, in the regulation of the processes of nerve conduction and muscle contractions, in maintaining stable cardiac activity. It has a tonic, antitoxic effect.
Phosphorus is a constituent of bone tissue, nucleoproteins and phospholipids. He takes part in all the processes of assimilation in the body of the animal, has a positive effect on the metabolism in the tissues of the body.
Magnesium participates in the metabolism of phosphorus and carbohydrates as a coenzyme. When administered parenterally, it blocks neuromuscular transmission and prevents the development of seizures.
The active ingredients of Calcite C50 are in a physiological ratio, are well and quickly absorbed after parenteral administration.
Indications
They are used in a set of measures for the treatment and prevention of diseases of farm animals during: tetany (during pregnancy, lactation, during transportation, grazing, etc.); paresis caused by a lack of calcium and phosphorus; metabolic disorders of calcium, phosphorus, magnesium (rickets, osteodystrophy, osteomalacia, etc.); poisoning with lead, fluorine, oxalic acid (as an additional agent in complex treatment); toxicosis, allergies.
Doses and method of administration
The drug is administered to animals intravenously, intramuscularly or subcutaneously in the following doses:
Kind of animal | Route of administration, disease | Dosage |
Cattle | administered intravenously, intramuscularly and subcutaneously in the treatment of acute calcium deficiency and postpartum hypocalcemia | 200-220 ml / 500 kg of animal weight |
Cattle | injected intramuscularly and subcutaneously for the prevention of metabolic disorders of calcium, phosphorus and magnesium | 100-150ml / 500kg animal weight |
Calves, pigs, sheep and goats | injected intravenously, intramuscularly and subcutaneously | 15ml / 50kg animal weight |
Piglets | injected intravenously, intramuscularly and subcutaneously | 1.5 ml / 5 kg of animal weight |
Dogs | injected intravenously, intramuscularly and subcutaneously | 2ml / 10kg animal weight |
Cats | injected intravenously, intramuscularly and subcutaneously | 0.5ml / 2.5kg mass |
Side effects
When using the drug in accordance with this instruction, side effects and complications in animals, as a rule, are not observed.
Contraindications
The drug is contraindicated in hypercalcemia, acidosis, severe renal dysfunction, atrial fibrillation, hypersensitivity to the components of the drug. Calcite C 50 is not recommended for animals simultaneously with digitalis preparations, vitamin D and its analogs.
Special instructions
No special precautions are provided. Products of animal origin after the application of Calcite C 50 are used on a general basis.
Storage conditions
In sealed manufacturer’s packaging in a dry, protected from direct sunlight, out of reach of children and animals, separately from food and feed at temperatures from 0 ° C to 30 ° C.
Shelf life
3 years from the date of production, after opening the bottle – 28 days.
Release form
The drug is released in glass bottles of 100 ml, 250 and 500 ml in plastic bottles.